New combo therapy aims to knock down prostate cancer quickly

NCT ID NCT05346848

Recruiting now Disease control Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with a certain type of prostate cancer that is not too advanced but has some higher-risk features. It tests whether adding a short course of the drug darolutamide to standard radiation therapy can lower PSA levels to a very low target (0.1 ng/mL or less) at 6 months. About 62 participants will receive the combination, and researchers will monitor how well it controls the cancer over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Assitance Publique des Hôpitaux de Marseille - CHU La Timone
NOT_YET_RECRUITING

Marseille, 13385, France
CHP Saint-Grégoire
NOT_YET_RECRUITING

Saint-Grégoire, 35760, France
CHRU Besançon
NOT_YET_RECRUITING

Besançon, 25030, France
CHRU Brest - Hôpital Morvan
NOT_YET_RECRUITING

Brest, 29200, France
Clinique Pasteur
NOT_YET_RECRUITING

Toulouse, 31076, France
Hôpital de la Pitié Salpétrière
NOT_YET_RECRUITING

Paris, 75651, France
IUCT Oncopôle
NOT_YET_RECRUITING

Toulouse, 31059, France
Institut Bergonie
RECRUITING

Bordeaux, 33076, France
Institut de Cancérologie de l'Ouest - Site René Gauducheau
NOT_YET_RECRUITING

Saint-Herblain, 44805, France
Sainte Catherine, Institut du Cancer Avignon-Provence
NOT_YET_RECRUITING

Avignon, 84918, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.